[1]张静静,李 青,王丹阳,等.血清KL-6 水平检测在临床间质性肺病诊断中的研究进展[J].现代检验医学杂志,2022,37(04):198-204.[doi:10.3969/j.issn.1671-7414.2022.04.039]
　ZHANG Jing-jing,LI Qing,WANG Dan-yang,et al.Research Progress of Serum KL-6 Levels in Clinical Interstitial Lung Disease Diagnosis[J].Journal of Modern Laboratory Medicine,2022,37(04):198-204.[doi:10.3969/j.issn.1671-7414.2022.04.039]
点击复制

血清KL-6 水平检测在临床间质性肺病诊断中的研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年04期
页码:
198-204
栏目:
综述
出版日期:
2022-07-15

文章信息/Info

Title:
Research Progress of Serum KL-6 Levels in Clinical Interstitial Lung Disease Diagnosis
文章编号:
1671-7414（2022）04-198-07
作者:
张静静1; 2; 李 青1; 2; 王丹阳1; 2; 王水利2; 杜 洁2
1. 西安医学院，西安 710068；2. 陕西省人民医院, 西安 710068
Author(s):
ZHANG Jing-jing1; 2; LI Qing1; 2; WANG Dan-yang1; 2; WANG Shui-li2; DU Jie2
1.Xi’an Medical University, Xi’an 710068, China; 2. Shaanxi Provincial People’s Hospital, Xi’an 710068, China
关键词:
血清涎液化糖链抗原 6; 间质性肺病
分类号:
R563.13；R392.11
DOI:
10.3969/j.issn.1671-7414.2022.04.039
文献标志码:
A
摘要:
间质性肺病（interstitial lung disease，ILD）是一大类疾病，有病因繁多、发病机制复杂、诊断及治疗困难等特点。近年来，该病的发病率逐年上升。因早期症状和体征缺乏特异度，该病的诊断仍具挑战性。多项研究表明血清涎液化糖链抗原-6（krebs von den lungen-6，KL-6）与该病的发生、发展有密切关系，且具有操作简单、灵敏度及特异度高、成本低等优势，对间质性肺病诊断、预后判定及动态监测具有一定临床价值，目前国内尚无血清KL-6 用于诊断间质性肺病阈值的相关指南或专家共识，因此该文着重阐述血清KL-6 水平检测在临床间质性肺病诊断中的研究进展。
Abstract:
Interstitial lung disease （ILD）is one of the major diseases, which is characterized by various etiologies, complicated pathogenesis, and difficulty in diagnosis and treatment. In recent years, the incidence of the disease has been increasing year by year. The diagnosis of this disease remains challenging due to the lack of specificity of early symptoms and signs. Many studies have shown that Krebs von den Lungen 6 （KL-6）is closely related to the occurrence and development of this disease, and has the advantages of simple operation, high sensitivity and specificity, and low cost, there is no guideline or expert consensus on the use of serum KL-6 as a diagnostic threshold for ILD, therefore, this article focuses on the development of serum KL-6 detection in clinical I ILD diagnosis.

参考文献/References:

[1] LAI Yunxia, WEI Xinru, YE Ting. Interrelation between fibroblasts and T cells in fibrosing interstitial lung diseases[J]. Frontiers in immunology, 2021,12:747335.
[2] ZHANG Hongying, CHEN Lizhou, WU Luling,et al. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA compliant systematic review and metaanalysis[ J]. Medicine, 2020, 99(16): e19493.
[3] TRAVIS W D, COSTABEL U, HANSELL D M, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. American Journal of Respiratory and Critical Care Medicine, 2013,188(6): 733-748.
[4] SAIRA A, NASEEM A, NAUSHEEN S, et al.Epidemiology and clinico-radiological features of interstitial lung diseases[J]. Pakistan Journal of Medical Sciences, 2020, 36(3): 365-370.
[5] WIJSENBEEK M, LEE J S, UDWADIA Z,et al.Editorial: interstitial lung disease around the world[J].Frontiers in Medicine, 2022, 9: 865334.
[6] D'ALESSANDRO M, BERGANTINI L, BARGAGLI E, et al. Extracellular vesicles in pulmonary fibrosis models and biological fluids of interstitial lung disease patients: a scoping review[J]. Life (Basel, Switzerland),2021, 11(12): 1401.
[7] MONTERO P, MILARA J, ROGER I, et al. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms[J]. International Journal of Molecular Sciences, 2021, 22(12): 6211.
[8] XUE Mingshan, CAI Chuanxu, ZENG Yifeng, et al.Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features[J].Medicine, 2021, 100(4): e24260.
[9] NAMBA M, HATTORI N, HAMADA H, et al. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cellmediated cytotoxicity by capping MUC1[J]. Cancer Lett,2019 ,442:31-39.
[10] 邢瑞青, 彭道荣, 刘杨. 血清CA199,KL-6 和PIVKA Ⅱ水平联合检测在胰腺癌诊断中的应用价值分析[J]. 现代检验医学杂志, 2021, 36(5):100-104. XING Ruiqing, PENG Daorong, LIU Yang. Application value of combined detection of serum CA199,KL-6 and PIVKA-Ⅱ levels in the diagnosis of patients with pancreatic cancer [J]. Journal of Modern Laboratory Medicine, 2021,36(5):100-104.
[11] HU Yang, WANG Liusheng, JIN Yueping, et al. Serum Krebs von den lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients[J]. The Clinical Respiratory Journal, 2017, 11(3): 337-345.
[12] HE Qiurong, TANG Yufan, HUANG Jie, et al. The value of KL-6 in the diagnosis and assessment of interstitial lung disease[J]. American Journal of Translational Research, 2021, 13(8): 9216-9223.
[13] ISHIKAWA N, HATTORI N, YOKOYAMA A, et al.Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respiratory Investigation,2012, 50(1): 3-13.
[14] BONELLA F, COSTABEL U. Biomarkers in connective tissue disease associated interstitial lung disease[J]. Seminars in Respiratory and Critical Care Medicine, 2014, 35(2): 181-200.
[15] ZHONG Danli, WU Chanyuan, BAI Jingjing, et al.Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases:A metaanalysis[ J]. Medicine (Baltimore), 2020, 99(16): 19695.
[16] INOUE Y, KANER R J, GUIOT J, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype[J]. CHEST,2020, 158(2): 646-659.
[17] SHAO Tihong, SHI Xiaodong, YANG Shanpeng, et al.Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations[J]. Frontiers in Immunology,2021, 12: 684-699.
[18] KO U W, CHO E J, OH H, et al. Serum Krebs von den lungen-6 level predicts disease progression in interstitial lung disease[J]. PLoS One, 2020, 15(12): e244114.
[19] ZHENG Muhan, LOU Aiju, ZHANG Haoru, et al.Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population[J].Rheumatology and Therapy, 2021, 8(1): 517-527.
[20] HANAOKA M, KATSUMATA Y, KAWASUMI H, et al. KL-6 is a long term disease activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short term disease activity biomarker[J]. Modern Rheumatology, 2019, 29(4): 625-632.
[21] KILINC A A, ARSLAN A, YILDIZ M, et al. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study[J].Rheumatology International, 2020, 40(10): 1701-1706.
[22] MA Hua, LU Junhui, SONG Yuanyuan, et al. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease[J]. BMC Pulmonary Medicine, 2020,20(1): 6.
[23] RICHELDI L, COLLARD H R, JONES M G. Idiopathic pulmonary fibrosis [J]. Lancet,2017,389(10082):1941-1952.
[24] CABRERA CESAR E, LOPEZ-LOPEZ L, LARA E,et al. Serum biomarkers in differential diagnosis of idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease[J]. Journal of Clinical Medicine, 2021, 10(14): 3167.
[25] KISHABA T. Evaluation and management of idiopathic pulmonary fibrosis[J]. Respiratory Investigation, 2019,57(4): 300-311.
[26] JIANG Ying, LUO Qun, HAN Qian, et al. Sequential changes of serum KL-6 predict the progression of interstitial lung disease[J]. Journal of Thoracic Disease,2018, 10(8): 4705-4714.
[27] JIANG Dingyuan, XIAO Huijuan, DONG Run, et al.Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis[J]. Clin Respir J,2022 ,16(3):234-243.
[28] WAKAMATSU K, NAGATA N, KUMAZOE H, et al.Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis[J].Respiratory Investigation, 2017, 55(1): 16-23.
[29] XUE Changjiang, WU Na, LI Xue, et al. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis:a case–control study[J]. BMC Pulmonary Medicine,2017, 17(1): 144.
[30] 李瑞文, 黄明, 李聪, 等. 矽肺患者血FSTL1, KL-6,TNF-α, sIL-2R 水平变化及其临床意义[J]. 广东医学, 2019, 40(10):1396-1400． LI Ruiwen, HUANG Ming, LI Cong, et al. The expression and signficance of serum FSTL1, KL-6, TNF-α and sIL-2R levels in silicosis patients [J].Guangdong Medical Journal,2019,40(10):1396-1400.
[31] 王文美, 宋海燕, 庞燕, 等．血清涎液化糖链抗原 6检测在矽肺病早期预防中的价值[J]．实用预防医学,2018, 25(12):1528-1530. WANG Wenmei, SONG Haiyan, PANG Yan, et al.Value of detection of serum Krebs von den Lungen-6 in the early prevention of silicosis [J]. Practical Preventive Medicine, 2018,25(12):1528-1530.
[32] 袁宝军, 李超, 高利常, 等. 壹期煤工尘肺患者血清KL-6 水平测定及意义[J]. 标记免疫分析与临床,2018, 25(12):1881-1884. YUAN Baojun, LI Chao, GAO Lichang, et al. The significance of serum KL-6 levels in patients with stage I coal worker’s pneumoconiosis [J]. Labeled Immunoassays and Clinical Medicine, 2018, 25(12):1881-1884.
[33] 陈冉, 张海东, 杨飞飞, 等. 染矽尘大鼠结缔组织生长因子和Ⅱ型肺泡细胞表面抗原的表达[J]. 环境与职业医学, 2017, 34(1): 58-62. CHEN Ran, ZHANG Haidong, YANG Feifei, et al.Expression of connective tissue growth factor and type II alveolar cell surface antigen in silica treated rats [J].Journal of Environmental and Occupational Medicine,2017,34(1):58-62.
[34] JACOBSON J R. Sphingolipids as a novel therapeutic target in radiation induced lung injury[J]. Cell Biochemistry and Biophysics, 2021, 79(3): 509-516.
[35] 刘望. 肺癌放射治疗致放射性肺炎的相关因素分析[J]. 中国卫生标准管理, 2021, 12(1):60-61. LIU Wang. Analysis of related factors of radiation pneumonitis caused by radiotherapy of lung cancer [J].China Health Standard Management, 2021,12(1):60-61.
[36] 吴丽娜, 高弋, 李沃松, 等．KL-6 在非小细胞肺癌术后辅助治疗性肺损伤中的诊断价值[J]. 协和医学杂志, 2021, 12(4): 496-502. WU Lina, GAO Yi, Li Wosong, et al. Application value of serum Kreb von den Lungen-6 in the adjuvant treatment of lung injury after non-small cell lung cancer surgery [J]. Medical Journal of Peking Union Medical College Hospital, 2021,12(4):496-502.
[37] 陈津, 彭伟, 崔兆磊, 等. 食管癌放疗患者血清涎液化糖链抗原水平检测在预测放射性肺炎的风险评估[J]. 现代检验医学杂志, 2020, 35(3): 126-128,156. CHEN Jin, PENG Wei, CUI Zhaolei, et al. Serum KL-6 predicts the risk of pneumonitis induction after radiotherapy of esophageal cancer[J]. Journal of Modern Laboratory Medicine, 2020, 35(3):126-128,156.
[38] JI Yuan, BOURKE S J, SPEARS M. Krebs von den Lungen-6(KL-6)is a pathophysiological biomarker of early-stage acute hypersensitivity pneumonitis among pigeon fanciers[J]. Clinical and Experimental Allergy,2020, 50(12): 1391-1399.
[39] MOSTAFA A I, SALEM A E, AHMED H M, et al.Role of Krebs von den lungen-6(KL-6)in assessing hypersensitivity pneumonitis[J]. Tuberculosis and Respiratory Diseases, 2021, 84(3): 200-208.
[40] SALISBURY M L, MYERS J L, BELLOLI E A, et al.Diagnosis and treatment of fibrotic hypersensitivity pneumonia. where we stand and where we need to go[J]. American Journal of Respiratory and Critical Care Medicine, 2017, 196(6): 690-699.
[41] HANZAWA S, TATEISHI T, ISHIZUKA M, et al.Changes in serum KL-6 levels during short term strict antigen avoidance are associated with the prognosis of patients with fibrotic hypersensitivity pneumonitis caused by avian antigens[J]. Respiratory Investigation,2020, 58(6): 457-464.
[42] SURYANANDA T D, YUDHAWATI R. Association of serum KL-6 levels on COVID-19 severity: A crosssectional study design with purposive sampling[J]. Ann Med Surg (Lond),2021,69:102673.
[43] ANDRO P W, BENDIX S W, JANUAR E A, et al.Serum Krebs von den Lungen-6 for predicting the severity of COVID 19 lung injury:a systematic review and Meta-Analysis[J]. Iranian Biomedical Journal,2021, 25(6): 381-389.
[44] NAKAMURA H, MIYAGI K, OTSUKI M, et al. Serum KL-6 can distinguish between different phenotypes of severe COVID-19[J]. Journal of Medical Virology,2021, 93(1): 158-160.
[45] AWANO N, INOMATA M, KUSE N, et al. Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019[J]. Respiratory Investigation, 2020, 58(6): 440-447.
[46] ACKERMANN M, VERLEDEN S E, KUEHNEL M,et al. Pulmonary vascular endothelialitis, thrombosis,and angiogenesis in covid 19[J]. The New England Journal of Medicine, 2020, 383(2): 120-128.
[47] D'ALESSANDRO M, CAMELI P, REFINI R M, et al. Serum KL-6 Concentrations as a novel biomarker of severe COVID 19[J]. Journal of Medical Virology,2020, 92(10): 2216-2220.
[48] YAMAYA T, HAGIWARA E, BABA T, et al. Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019[J]. Respiratory Investigation, 2021, 59(5):596-601.
[49] GUO Wenliang, ZHOU Ziqing, CHEN Lu, et al.Serum KL-6 in pulmonary alveolar proteinosis: China compared historically with Germany and Japan[J].Journal of Thoracic Disease, 2017, 9(2): 287-295.
[50] BERGANTINI L, BIANCHI F, CAMELI P, et al.Prognostic biomarkers of sarcoidosis: A comparative study of serum chitotriosidase, ACE, Lysozyme, and KL-6[J]. Dis Markers, 2019, 2019: 8565423.
[51] 谭立明, 卢晓霞, 张倩, 等. 血清KL-6, DD 及CRP在ANCA 相关性血管炎合并间质性肺病检测中的临床价值[J]. 中国免疫学杂志, 2021, 37(8): 983-987. TAN Liming, LU Xiaoxia, ZHANG Qian, et al. Clinical value of serum KL-6,DD and CRP in ANCA-associated vasculitis with interstitial lung disease [J]. Chinese Journal of Immunology, 2021,37(8):983-987.

备注/Memo

备注/Memo:
作者简介：张静静（1996-），女，硕士在读，住院医师，研究方向：呼吸系统疾病，E-mail: 331269171@qq.com。
通信作者：杜洁（1983-），女，博士在读，副主任医师，研究方向：呼吸系统疾病，E-mail: dujie123._@163.com。
更新日期/Last Update: 1900-01-01